Bank of Montreal Can grew its stake in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 19.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 92,379 shares of the biopharmaceutical company’s stock after purchasing an additional 15,030 shares during the period. Bank of Montreal Can owned about 0.18% of Vanda Pharmaceuticals worth $2,120,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Renaissance Technologies LLC lifted its holdings in shares of Vanda Pharmaceuticals by 2.5% during the second quarter. Renaissance Technologies LLC now owns 1,681,250 shares of the biopharmaceutical company’s stock valued at $32,028,000 after purchasing an additional 41,200 shares during the last quarter. Xact Kapitalforvaltning AB purchased a new stake in shares of Vanda Pharmaceuticals during the second quarter valued at $240,000. BlackRock Inc. lifted its holdings in shares of Vanda Pharmaceuticals by 16.3% during the second quarter. BlackRock Inc. now owns 4,960,924 shares of the biopharmaceutical company’s stock valued at $94,506,000 after purchasing an additional 693,922 shares during the last quarter. Virginia Retirement Systems ET AL purchased a new stake in shares of Vanda Pharmaceuticals during the second quarter valued at $754,000. Finally, Macquarie Group Ltd. lifted its holdings in shares of Vanda Pharmaceuticals by 12.1% during the second quarter. Macquarie Group Ltd. now owns 2,555,004 shares of the biopharmaceutical company’s stock valued at $48,673,000 after purchasing an additional 276,057 shares during the last quarter. 93.92% of the stock is owned by institutional investors and hedge funds.
Several equities research analysts have recently commented on VNDA shares. TheStreet raised Vanda Pharmaceuticals from a “c” rating to a “b-” rating in a report on Friday, October 26th. Oppenheimer set a $27.00 price objective on Vanda Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 2nd. Seaport Global Securities reissued a “buy” rating and issued a $26.00 price objective on shares of Vanda Pharmaceuticals in a research note on Thursday, August 2nd. Stifel Nicolaus started coverage on Vanda Pharmaceuticals in a research note on Thursday, September 13th. They issued a “buy” rating and a $30.00 price objective for the company. Finally, Citigroup increased their price objective on Vanda Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a research note on Tuesday, October 16th. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Vanda Pharmaceuticals presently has an average rating of “Buy” and an average price target of $27.43.
Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Wednesday, November 7th. The biopharmaceutical company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.18. The firm had revenue of $49.13 million during the quarter, compared to the consensus estimate of $49.44 million. Vanda Pharmaceuticals had a return on equity of 0.68% and a net margin of 0.73%. The business’s revenue for the quarter was up 18.9% on a year-over-year basis. During the same period in the prior year, the business earned ($0.03) EPS. As a group, analysts predict that Vanda Pharmaceuticals Inc. will post -0.04 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “Bank of Montreal Can Has $2.12 Million Stake in Vanda Pharmaceuticals Inc. (VNDA)” was first reported by WKRB News and is the property of of WKRB News. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://www.wkrb13.com/2018/11/09/bank-of-montreal-can-has-2-12-million-stake-in-vanda-pharmaceuticals-inc-vnda.html.
Vanda Pharmaceuticals Profile
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.
Want to see what other hedge funds are holding VNDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA).
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.